Filter Results:
(446)
Show Results For
- All HBS Web
(632)
- People (2)
- News (55)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Show Results For
- All HBS Web
(632)
- People (2)
- News (55)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Sort by
- October 1987
- Case
T Cell Sciences, Inc.
By: Francis Aguilar
Keywords: Biotechnology Industry
Aguilar, Francis. "T Cell Sciences, Inc." Harvard Business School Case 388-001, October 1987.
- 02 Aug 2004
- Research & Ideas
Health Care Research and Prospects
is a lot other work at the school going on around these issues by many other faculty. For instance, Dave Scharfstein is doing great work on how capital market forces influence the development strategies of biotechnology companies. David... View Details
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Biotechnology Industry; Biotechnology Industry
Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)
- September 2023 (Revised April 2024)
- Case
Atomwise: Strategic Opportunities in AI for Pharma
By: Satish Tadikonda
Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details
Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Biotechnology Industry; Biotechnology Industry
Tadikonda, Satish. "Atomwise: Strategic Opportunities in AI for Pharma." Harvard Business School Case 824-043, September 2023. (Revised April 2024.)
- January 2014
- Supplement
Amgen Inc.: Pursuing Innovation and Imitation? (B)
By: Ian Mackenzie
The (B) case reveals that Sharer decided that Amgen should enter the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The... View Details
Mackenzie, Ian. "Amgen Inc.: Pursuing Innovation and Imitation? (B)." Harvard Business School Supplement 714-426, January 2014.
- June 2012
- Case
GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships
By: Arthur A. Daemmrich and Ian McKown Cornell
Three years into a major public-private partnership between GlaxoSmithKline and Fiocuz, Brazil's principal health institute, the company assesses technology transfer and joint research under the agreement. GSK was selling its Synflorix vaccine (against pediatric... View Details
Keywords: Public-Private Partnerships; Business and Government Relations; Foreign Direct Investment; Health Care and Treatment; Globalized Firms and Management; Biotechnology Industry; Biotechnology Industry; Brazil
Daemmrich, Arthur A., and Ian McKown Cornell. "GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships." Harvard Business School Case 712-049, June 2012.
- April 2011
- Supplement
Roche's Acquisition of Genentech (CW)
By: Bo Becker
Spreadsheet for case 210040. View Details
- March 2011 (Revised June 2012)
- Case
Office of Technology Transfer - Shanghai Institutes for Biological Sciences
By: Willy Shih, Sen Chai, Kamen Bliznashki and Courtney Hyland
Gordon Zong is trying to teach Chinese universities and research institutes how to do effective technology transfer and IP licensing, but he is trying to do it in an environment with weak property rights and an underdeveloped support infrastructure. As the managing... View Details
Keywords: Multinational Firms and Management; Patents; Knowledge Management; Law Enforcement; Business and Government Relations; Research and Development; Biotechnology Industry; Biotechnology Industry; China
Shih, Willy, Sen Chai, Kamen Bliznashki, and Courtney Hyland. "Office of Technology Transfer - Shanghai Institutes for Biological Sciences." Harvard Business School Case 611-057, March 2011. (Revised June 2012.)
- 24 Jun 2008
- Conference Presentation
The effect of heterogeneous institutional actors on entrepreneurial activity and resource attainment in the U.S. biodiesel industry
By: Shon R. Hiatt
- 2010
- Working Paper
Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe
By: Christopher C. Liu and Toby E. Stuart
In innovative industries, private-sector companies increasingly are participants in open communities of science and technology. To participate in the system of exchange in such communities, firms often publicly disclose what would otherwise remain private discoveries.... View Details
Keywords: For-Profit Firms; Higher Education; Information Publishing; Innovation and Invention; Science-Based Business; Social and Collaborative Networks; Boundaries; Biotechnology Industry; Biotechnology Industry
Liu, Christopher C., and Toby E. Stuart. "Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe." Harvard Business School Working Paper, No. 11-012, August 2010.
- November 2007
- Class Lecture
The Baby Business (FSS)
By: Debora L. Spar
In vitro fertilization and genetic screening are possible with the advent of biotechnology. International adoptions, surrogacy, and other approaches to family planning are on the rise. But few rules govern these measures, medical costs can be prohibitive, and... View Details
Keywords: Governing Rules, Regulations, and Reforms; Policy; Demand and Consumers; Business and Government Relations; Business and Stakeholder Relations; Genetics; Societal Protocols; Commercialization; Biotechnology Industry; Biotechnology Industry
Spar, Debora L. "The Baby Business (FSS)." Harvard Business School Class Lecture 708-701, November 2007.
- November 2007
- Case
Antegren: A Beacon of Hope
By: Joshua D. Margolis, Thomas J. DeLong and Terence Heymann
The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA. The first in a series focuses on operational decisions triggered by the drive for early approval. Sparks discussion... View Details
Keywords: Demand and Consumers; Leadership; Ethics; Corporate Social Responsibility and Impact; Decision Choices and Conditions; Crisis Management; Health Testing and Trials; Biotechnology Industry; Biotechnology Industry
Margolis, Joshua D., Thomas J. DeLong, and Terence Heymann. "Antegren: A Beacon of Hope." Harvard Business School Case 408-025, November 2007.
- June 2004 (Revised May 2005)
- Case
Judah Folkman and the War on Cancer
Judah Folkman, professor in the Division of Vascular Biology at Children's Hospital in Boston, is considering how best to advance the research in his lab in an era where biomedical research has gotten more interdisciplinary and collaborative. Specifically, Folkman has... View Details
Keywords: Conflict of Interests; Leadership; Research; Personal Development and Career; Health Care and Treatment; Collaborative Innovation and Invention; Biotechnology Industry; Biotechnology Industry; Boston
West, Jonathan, Ambuj Sagar, and Mona Ashiya. "Judah Folkman and the War on Cancer." Harvard Business School Case 604-091, June 2004. (Revised May 2005.)
- September 1995
- Case
Ares-Serono
By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop
Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational... View Details
Keywords: Geographic Location; Globalized Firms and Management; Asset Management; Balance and Stability; Expansion; Digital Platforms; Leadership Development; Health Care and Treatment; Transformation; Family Business; Problems and Challenges; Biotechnology Industry; Biotechnology Industry; Switzerland; Europe
Yoshino, Michael Y., Jean-Pierre Jeannet, and Carin-Isabel Knoop. "Ares-Serono." Harvard Business School Case 396-035, September 1995.
- 01 Nov 2024
- In Practice
Layoffs Surging in a Strong Economy? Advice for Navigating Uncertain Times
decision about entrepreneurship Starting your own company after a layoff is a significant decision. While it may seem like an opportune time, research suggests there are some important considerations. “Entrepreneurs coming from high-tech sectors such as View Details
- 05 Jan 2011
- Op-Ed
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress
In light of the latest developments of the on-again, off-again, on-again government funding of human embryonic stem-cell research, it is time to consider the devastating implications of this chaotic funding environment. And to do that, one needs to understand how a... View Details
- May 2015
- Case
Transforming Alkermes into a Global Biopharmaceutical Company
By: C. Fritz Foley and Nicholas Haas
In the summer of 2011, Jim Frates, CFO of Alkermes faced choices about how to finance the acquisition of Dublin, Ireland-based Elan Drug Technologies (EDT)—a deal that was expected to close in the fall. The case describes the history of Alkermes, provides information... View Details
Keywords: Financing; Debt; Merger; CFO; Financial Management; Biotechnology Industry; Biotechnology Industry; United States; Europe
Foley, C. Fritz, and Nicholas Haas. "Transforming Alkermes into a Global Biopharmaceutical Company." Harvard Business School Case 215-079, May 2015.
- April 2011
- Teaching Note
Office of Technology Transfer - Shanghai Institutes for Biological Sciences (TN)
By: Willy Shih and Sen Chai
Teaching Note for 611057. View Details
- March 2011 (Revised February 2012)
- Case
Innovation and Growth at Actelion Ltd.
By: Gary P. Pisano, Daniela Beyersdorfer and Ruth Dittrich
In late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven... View Details
Keywords: Business Model; Talent and Talent Management; Innovation and Management; Leadership; Growth and Development Strategy; Product Development; Organizational Culture; Research and Development; Biotechnology Industry; Biotechnology Industry; Switzerland
Pisano, Gary P., Daniela Beyersdorfer, and Ruth Dittrich. "Innovation and Growth at Actelion Ltd." Harvard Business School Case 611-065, March 2011. (Revised February 2012.)
- February 2009
- Case
Avid Radiopharmaceuticals: The Venture Debt Question
By: Matthew Rhodes-Kropf and Ann Leamon
The CEO of a promising biotech company must decide how to respond to the macro-economic slump of late 2008. He had planned to pursue an aggressive schedule, moving the firm's Alzheimer's and Parkinson's disease imaging compounds through clinical trials and into the... View Details
Keywords: Financial Crisis; Entrepreneurship; Borrowing and Debt; Venture Capital; Financial Management; Investment; Health Testing and Trials; Expansion; Biotechnology Industry; Biotechnology Industry
Rhodes-Kropf, Matthew, and Ann Leamon. "Avid Radiopharmaceuticals: The Venture Debt Question." Harvard Business School Case 809-086, February 2009.